

PRESS RELEASE

Cordlife Introduces MetaScreen Metabolic Screening Service in India

Key Facts

- **MetaScreen allows detection of as many as 110 metabolic disorders from urine samples.**
- **MetaScreen allows Cordlife to further capitalise on fast-rising India middle class, whose population is expected to grow 67% to 267 million by 2015.**
- **In line with Cordlife's vertical growth plan to improve economies of scope via offering of complementary products and services that cater to the mother and child segment.**

SINGAPORE, 10 October 2013 – **Cordlife Group Limited** (“Cordlife”, and together with its subsidiaries, the “Group”), a multi-product healthcare company catering to the mother and child segment, announced today that its Indian subsidiary Cordlife Sciences (India) Pvt. Ltd. (“Cordlife India”), has introduced an advanced non-invasive metabolic screening service known as MetaScreen. This initiative is part of the Cordlife's vertical growth plan to offer complementary products and services that cater to the mother and child segment, which will benefit the Group through better economies of scope.

MetaScreen is a comprehensive set of metabolic screening test specially designed for both newborn babies and adults. The service can detect as many as 110 inborn errors of metabolism from urine samples. Metabolic disorders are usually not apparent at the time of birth. If left undiagnosed and untreated, the baby can develop irreversible damages such as neurological impairment and physical deformities. Hence, early detection is critical in preventing adverse effects and providing essential care. Most countries in the European Union and some parts of Asia and United States have already made newborn screening compulsory.

The introduction of MetaScreen is the latest milestone for Cordlife. Mr Jeremy Yee, Executive Director and Group CEO of Cordlife said, “We believe that growth for the Group is sustainable in the long term through the interaction of economies of scale and scope. This essentially means the expansion of the Group's geographical footprint as part of our horizontal growth plans, as well as vertical growth in terms of the scope of products and services that we will be providing. The introduction of MetaScreen in India is in line with our plans to grow through complementary services and through partnerships and collaborations.”

The initial public offering of Cordlife's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this release.

According to a report released by Deloitte & Touche Financial Advisory Services Limited in April this year, India represents one of the high growth Asian markets with a burgeoning middle class. The population of the Indian middle class is expected to increase to 267 million by 2015, or 67% from the current level, according to the National Council for Applied Economic Research. India currently has the second largest population in the world and the number of new births is likely to keep rising as India is predicted to exceed China, becoming the most populous nation by 2025. An annual new births of 25.7 million is forecasted by the end of 2016 according to a market report from EIU.

Just as newborn screening is widely recognised by medical professionals as an essential healthcare, the fast-rising middle class in India are becoming increasingly aware of the importance of their children's healthcare needs as shown by the 2007–2011 Compound Annual Growth Rate of annual incremental storage units for private cord blood banks of 35%. MetaScreen is a natural extension of Indian parents' desire for better healthcare options for their children. Providing parents with early critical information on the health status of the child will help ensure the future welfare of the child.

Mr Yee continued: "At the heart of our new service MetaScreen is helping parents secure their child's future well-being. Cordlife, with its expertise and access to best-available technology, allows them to do exactly this, preparing for any eventuality and safeguarding their family's health."

Cordlife offers MetaScreen through their strategic collaboration with Navigene Genetic Science, a genetic diagnostic and research company. The service will be made available by Cordlife India through their existing collaborative network of hospitals, and physicians. Compared to other similar screening services that require blood for testing, MetaScreen is a non-invasive and painless form of screening. Cordlife has plans to introduce MetaScreen to other entities in the Group.

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and tissue banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore¹. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013.

Cordlife collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. In May 2013, Cordlife Technologies Pte. Ltd., a wholly-owned subsidiary of Cordlife Group Limited, launched umbilical cord tissue banking service in Singapore. The storage and banking of umbilical cord tissue services provided in Singapore is currently not licensed by the Ministry of Health, Singapore. This service is provided on a research/clinical trial basis.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; and Baby Kingdom Top 10 Family Brand Award 2012². In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the “Most Transparent Company Award 2012”

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

² Awarded to Cordlife (Hong Kong) Limited

New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, "Best Investor Relations Award".

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Gabriel Tan / Mr Kamal Samuel
OFFICE : 6438-2990
EMAIL : gabriel@financialpr.com.sg /
kamal@financialpr.com.sg
